Cited by 874HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 73 of the 83 references it cites were found in a registry or an index.

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Open access

Agus, David B, Akita, Robert W, Fox, William D, Lewis, Gail D, Higgins, Brian, Pisacane, Paul I, Lofgren, Julie A, Tindell, Charles, Evans, Douglas P, Maiese, Krista, Scher, Howard I, Sliwkowski, Mark X·2002·Cancer Cell

DOI 10.1016/s1535-6108(02)00097-1

Open this paper in CoChat — free account Open PDF

Abstract

ErbB2 is a ligand-less member of the ErbB receptor family that functions as a coreceptor with EGFR, ErbB3, and ErbB4. Here, we describe an approach to target ErbB2's role as a coreceptor using a monoclonal antibody, 2C4, which sterically hinders ErbB2's recruitment into ErbB ligand complexes. Inhibition of ligand-dependent ErbB2 signaling by 2C4 occurs in both low- and high-ErbB2-expressing systems. Since the ErbB3 receptor contains an inactive tyrosine kinase domain, 2C4 is very effective in blocking heregulin-mediated ErbB3-ErbB2 signaling. We demonstrate that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment.

Integrity signals

Registry

Crossref · 10.1016/s1535-6108(02)00097-1

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Self-citation
Real time quantitative PCR.Preprint
Heid, C., Stevens, J., Livak, K. J., & Williams, P. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,180
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
A novel method for real time quantitative RT-PCR.Preprint
Gibson, U. E., Heid, C., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.995 · Cited by 2,090
ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,617
The EGF receptor family as targets for cancer therapy
Mendelsohn, J. M., & Baselga, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,341
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001

Show all 83 references

Research works printed but not linked: 6

Agus, 1999, Prostate cancer cell cycle regulators, J. Natl. Cancer Inst., 91, 1869, 10.1093/jnci/91.21.1869 · DOI
Lewis, 1996, Growth regulation of human breast and ovarian tumor cells by heregulin, Cancer Res., 56, 1457
Nagabhushan, 1996, CWR22, Cancer Res., 56, 3042
Pinkas-Kramarski, 1996, Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions, EMBO J., 15, 2452, 10.1002/j.1460-2075.1996.tb00603.x · DOI
Tzahar, 1998, The ErbB-2/HER2 oncogenic receptor of adenocarcinomas, Biochim. Biophys. Acta, 1377, M25
Wainstein, 1994, CWR22, Cancer Res., 54, 6049

Sorted by citations

Items 301–400 of 874

Understanding EGFR Signaling in Breast Cancer and Breast Cancer Stem Cells: Overexpression and Therapeutic Implications
Alanazi, I. O., & Khan, Z. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.2.445 · Cited by 53
Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
Holloway, R. W., & Marignani, P. A. (2021) · Cancers · doi:10.3390/cancers13122922 · Cited by 56
Roles for neuregulins in human cancer
Stove, C. P., & Bracke, M. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-004-6917-6 · Cited by 54
A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization
Baselga, J. M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00098-3 · Cited by 53
Resistance to Anti-HER2 Therapies in Breast Cancer
Rimawi, M. F., Angelis, C. D., & Schiff, R. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e157 · Cited by 52
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications
Sánchez‐Martín, M., & Pandiella, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26358 · Cited by 52
Cellular Effects of HER3-Specific Affibody Molecules
Göstring, L., Malm, M., Höidén‐Guthenberg, I., Frejd, F. Y., Ståhl, S., Löfblom, J., & Gedda, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040023 · Cited by 52
Combination Treatment with HER-2 and VEGF Peptide Mimics Induces Potent Anti-tumor and Anti-angiogenic Responses in Vitro and in Vivo
Foy, K. C., Liu, Z., Phillips, G. S., Miller, M., & Kaumaya, P. T. P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.216820 · Cited by 52
SOX10 is a novel oncogene in hepatocellular carcinoma through Wnt/β-catenin/TCF4 cascade
Dangjun, Z., Bai, F., Zhang, X., Hu, M., Zhao, G., Zhao, Z., & Liu, R. (2014) · Tumor Biology · doi:10.1007/s13277-014-1893-1 · Cited by 52
Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells
Seoane, S., Montero, J. C., Ocaña, A., & Pandiella, A. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq315 · Cited by 52
Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition
Gale, M., Li, Y., Cao, J. P., Liu, Z. Z., Holmbeck, M. A., Zhang, M., Lang, S. M., Wu, L., DoCarmo, M., Gupta, S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3985 · Cited by 51
Peptide Vaccines of the HER-2/neu Dimerization Loop Are Effective in Inhibiting Mammary Tumor Growth In Vivo
Allen, S. D., Garrett, J. T., Rawale, S. V., Jones, A. L., Phillips, G. S., Forni, G., Morris, J. C., Oshima, R. G., & Kaumaya, P. T. P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.472 · Cited by 52
PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer
Zhang, H., Zhang, L., He, Y., Jiang, D., Sun, J. L., Luo, Q., Liang, H., Wang, T., Li, F., Tang, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217112 · Cited by 54
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
Collins, D. M., Jacob, W., Cejalvo, J. M., Ceppi, M., James, I., Hasmann, M., Crown, J. P., Cervantes, A. M. R., Weisser, M., & Bossenmaier, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177331 · Cited by 52
Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics
Hervent, A.-S., & Keulenaer, G. W. D. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012268 · Cited by 55
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3–p185her2/neu and the EGFR–p185her2/neu complexes
Cai, Z., Zhang, G., Zhou, Z., Bembas, K., Drebin, J. A., Greene, M. I., & Zhang, H. (2008) · Oncogene · doi:10.1038/onc.2008.13 · Cited by 50
Peptide Vaccines and Peptidomimetics Targeting HER and VEGF Proteins May Offer a Potentially New Paradigm in Cancer Immunotherapy
Kaumaya, P. T. P., & Foy, K. C. (2012) · Future Oncology · doi:10.2217/fon.12.95 · Cited by 51
Design, Synthesis, and Docking Studies of Peptidomimetics Based on HER2–Herceptin Binding Site with Potential Antiproliferative Activity Against Breast Cancer Cell lines
Satyanarayanajois, S. D., Villalba, S., Liu, J., & Lin, G. M. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00855.x · Cited by 50
Identification of Kinases Regulating Prostate Cancer Cell Growth Using an RNAi Phenotypic Screen
Whitworth, H., Bhadel, S., Ivey, M. L., Conaway, M. R., Spencer, A., Hernan, R. A., Holemon, H., & Gioeli, D. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038950 · Cited by 50
Study of inhibition effect of Herceptin on interaction between Heregulin and ErbB Receptors HER3/HER2 by single-molecule force spectroscopy
Shi, X., Xu, L., Yu, J., & Fang, X. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.05.023 · Cited by 50
Negative Regulation of HER2 Signaling by the PEST-type Protein-tyrosine Phosphatase BDP1
Gensler, M., Buschbeck, M., & Ullrich, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309527200 · Cited by 50
Molecular architecture of the ErbB2 extracellular domain homodimer
Hu, S., Sun, Y., Meng, Y., Wang, X., Yang, W., Fu, W., Guo, H., Qian, W., Hou, S., Li, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2713 · Cited by 49
Role of erbB3 receptors in cancer therapeutic resistance
Lee, Y., Ma, J., Lyu, H., Huang, J., Kim, A., & Liu, B. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt150 · Cited by 49
Diverse Antiapoptotic Signaling Pathways Activated by Vasoactive Intestinal Polypeptide, Epidermal Growth Factor, and Phosphatidylinositol 3-Kinase in Prostate Cancer Cells Converge on BAD
Sastry, K. S., Smith, A. J., Karpova, Y., Datta, S. R., & Kulik, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602928200 · Cited by 49
Atomic force microscopy study of the effect of HER 2 antibody on EGF mediated ErbB ligand–receptor interaction
Zhang, X., Shi, X., Li, X., Yuan, J., & Fang, X. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.11.005 · Cited by 49
Role of Erbin in ErbB2-dependent breast tumor growth
Tao, Y., Shen, C., Luo, S., Traoré, W., Marchetto, S., Santoni, M.-J., Xu, L., Wu, B., Shi, C., Mei, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407139111 · Cited by 52
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
Krop, I. E., Modi, S., LoRusso, P. M., Pegram, M. D., Guardino, E., Althaus, B., Lu, D., Strasak, A. M., & ELIAS, A. D. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0691-7 · Cited by 49
Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
Li, X., Xu, Y., Ding, Y., Li, C., Zhao, H. W., Wang, J., & Meng, S. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0862-5 · Cited by 50
A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action
Zhang, X., Chen, J., Weng, Z., Li, Q., Zhao, L., Yu, N., Deng, L., Xu, W., Yang, Y., Zhu, Z., et al. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.01.009 · Cited by 49
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
de Haas, S. L., Slamon, D. J., Martín, M., Press, M. F., Phillips, G. D. L., Lambertini, C., Prat, A., López-Valverde, V., Boulet, T., & Hurvitz, S. A. (2023) · Breast Cancer Research · doi:10.1186/s13058-022-01587-z · Cited by 47
HER2 in Solid Tumors: More than 10 Years Under the Microscope; where are we now?
Martin, V., Cappuzzo, F., Mazzucchelli, L., & Frattini, M. (2014) · Future Oncology · doi:10.2217/fon.14.19 · Cited by 48
Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer
Sun, L., Burnett, J., Gasparyan, M., Xu, F., Jiang, H., Lin, C.-C. A., Myers, I., Körkaya, H., Liu, Y., Connarn, J. N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9839 · Cited by 49
Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.
Zazo, S., Gónzález-Alonso, P., Martı́n-Aparicio, E., Chamizo, C., Cristóbal, I., Arpí, O., Rovira, A., Albanell, J., Eroles, P., Lluch, A. M., et al. (2016) · PubMed Central · Cited by 48
Ready to partner
Sliwkowski, M. X. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb0303-158 · Cited by 48
Self-citation
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer
Vu, T., Sliwkowski, M. X., & Claret, F. X. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.007 · Cited by 47
Self-citation
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
Sims, A. H., Zweemer, A. J. M., Nagumo, Y., Faratian, D., Muir, M., Dodds, M., Um, I. H., Kay, C., Hasmann, M., Harrison, D. J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.176 · Cited by 47
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models
Thomas, G., Chardès, T., Gaborit, N., Mollévi, C., Leconet, W., Robert, B., Radosevic‐Robin, N., Penault-Llorca, F. M., Gongora, C., Colombo, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2231 · Cited by 46
Targeted therapies in breast cancer
Rojo, F., Albanell, J., Rovira, A., Corominas, J. M., & Manzarbeitia, F. (2008) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2008.08.001 · Cited by 44
A pan-HER approach for cancer therapy: background, current status and future development
Huang, Z., Brdlik, C. M., Jin, P., & Shepard, H. M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802630427 · Cited by 45
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
Schwarz, L. J., Hutchinson, K. E., Rexer, B. N., Estrada, M. V., Ericsson, P. I. G., Sanders, M. E., Dugger, T. C., Formisano, L., Zotano, Á. G., Red-Brewer, M., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx065 · Cited by 48
Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators
Wang, S. E., Yu, Y., Criswell, T. L., DeBusk, L. M., Lin, P., Zent, R., Johnson, D. H., Ren, X., & Arteaga, C. L. (2010) · Oncogene · doi:10.1038/onc.2010.112 · Cited by 47
Targeting protein kinases in cancer therapy: a success?
Pearson, M. A., & Fabbro, D. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.6.1113 · Cited by 48
NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: Implications for tumor growth retardation and docetaxel sensitivity
Manandhar, S., Choi, B.-H., Jung, K.-A., Ryoo, I.-G., Song, M., Kang, S. J., Choi, H.-G., Kim, J.-A., Park, P.-H., & Kwak, M.-K. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.031 · Cited by 45
HER3 is required for the maintenance of neuregulin‐dependent and ‐independent attributes of malignant progression in prostate cancer cells
Soler, M., Mancini, F., Meca‐Cortés, Ó., Sánchez‐Cid, L., Rubio, N., López‐Fernández, S., Lozano, J. J., Blanco, J., Fernández, P. L., & Thomson, T. M. (2009) · International Journal of Cancer · doi:10.1002/ijc.24651 · Cited by 45
Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity
Nagumo, Y., Faratian, D., Mullen, P., Harrison, D. J., Hasmann, M., & Langdon, S. P. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0101 · Cited by 45
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
Morrow, P. K. H., Zambrana, F. R., & Esteva, F. J. (2009) · Breast Cancer Research · doi:10.1186/bcr2324 · Cited by 46
Targeting HER2 in Prostate Cancer: Where to Next?
Solit, D. B., & Rosen, N. X. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8187 · Cited by 45
EGFR trafficking: effect of dimerization, dynamics, and mutation
Schultz, D. F., Billadeau, D. D., & Jois, S. D. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1258371 · Cited by 48
Molecular mechanisms involving prostate cancer racial disparity.
Hatcher, D. M., Daniels, G., Osman, I., & Lee, P. (2009) · PubMed Central · Cited by 42
PC Cell–Derived Growth Factor Stimulates Proliferation and Confers Trastuzumab Resistance to Her-2-Overexpressing Breast Cancer Cells
Kim, W. E., & Serrero, G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2663 · Cited by 44
The HER2- and Heregulin β1 (HRG)–Inducible TNFR Superfamily Member Fn14 Promotes HRG-Driven Breast Cancer Cell Migration, Invasion, and MMP9 Expression
Asrani, K. V., Keri, R. A., Galisteo, R., Brown, S. A. N., Morgan, S. J., Ghosh, A., Tran, N. L., & Winkles, J. A. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0542 · Cited by 44
Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
Yarden, Y., & Wheeler, D. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2 · Cited by 44
Novel Systemic Therapies for Advanced Gastric Cancer
Kim, H. J., & Oh, S. C. (2018) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2018.18.e3 · Cited by 45
Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition
Chinnaiyan, P., Varambally, S., Tomlins, S. A., Ray, S. S., Huang, S., Chinnaiyan, A. M., & Harari, P. M. (2005) · International Journal of Cancer · doi:10.1002/ijc.21465 · Cited by 44
Development of an Autocrine Neuregulin Signaling Loop with Malignant Transformation of Human Breast Epithelial Cells
Li, Q., Ahmed, S. F., & Loeb, J. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1152 · Cited by 44
Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
Leung, W.-Y., Roxanis, I., Sheldon, H., Buffa, F. M., Li, J., Harris, A. L., & Kong, A. H. (2015) · Oncotarget · doi:10.18632/oncotarget.3296 · Cited by 42
A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action
Brack, S., Attinger-Toller, I., Schade, B., Mourlane, F., Klupsch, K., Woods, R., Hachemi, H., von der Bey, U., Koenig-Friedrich, S., Bertschinger, J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0046-t · Cited by 43
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer
Kennedy, S. P., Han, J. Z. R., Portman, N., Nobis, M., Hastings, J. F., Murphy, K. J., Latham, S. L., Cadell, A. L., Miladinovic, D., Marriott, G. R., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1127-y · Cited by 41
Advances in the strategies for designing receptor-targeted molecular imaging probes for cancer research
Ko, Y. J., Kim, W. J., Kim, K., & Kwon, I. C. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.030 · Cited by 44
A Phase II Trial with Trastuzumab and Pertuzumab in Patients with HER2-Overexpressed Locally Advanced and Metastatic Breast Cancer
Walshe, J. M., Denduluri, N., Berman, A. W., Rosing, D. R., & Swain, S. M. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.009 · Cited by 43
Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options
Ocaña, A., & Pandiella, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1630 · Cited by 44
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Gupta, A., Michelini, F., Shao, H., Yeh, C., Drago, J. Z., Liu, D., Rosiek, E., Romin, Y., Ghafourian, N., Thyparambil, S. P., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101792 · Cited by 50
HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells
Zhang, Y., Opresko, L. K., Shankaran, H., Chrisler, W., Wiley, H. S., & Resat, H. (2009) · BMC Cell Biology · doi:10.1186/1471-2121-10-78 · Cited by 42
Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab
Kawamoto, T., Ishige, K., Thomas, M. B., Yamashita‐Kashima, Y., Shu, S., Ishikura, N., Ariizumi, S., Yamamoto, M., Kurosaki, K., & Shoda, J. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-0984-5 · Cited by 42
Dynamically varying interactions between heregulin and ErbB proteins detected by single-molecule analysis in living cells
Hiroshima, M., Saeki, Y., Okada, M., & Sako, Y. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200464109 · Cited by 42
Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib
Huang, W., Wu, Q.-D., Zhang, M., Kong, Y., Cao, P.-R., Zheng, W., Xu, J., & Ye, M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.040 · Cited by 42
Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization
Mooso, B. A., Vinall, R. L., Tepper, C. G., Savoy, R. M., Cheung, J. P., Singh, S., Siddiqui, S., Wang, Y., Bedolla, R. G., Martinez, A. D., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0171 · Cited by 42
Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer
ElSahwi, K. S., Schwartz, P. E., & Santin, A. D. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.192 · Cited by 42
A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors
Albanell, J., Montagut, C. O., Jones, E. T., Pronk, L. C., Mellado, B., Beech, J., Gascón, P., Zugmaier, G., Brewster, M., Saunders, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1980 · Cited by 42
DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity
Perales‐Puchalt, A., Duperret, E. K., Yang, X., Hernández, P., Wojtak, K., Zhu, X., Jung, S.-H., Tello‐Ruiz, E., Wise, M. C., Montaner, L. J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126086 · Cited by 42
Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells
Kim, A., Liu, B., Ordonez‐Ercan, D., Alvarez, K. M., Jones, L. D., McKimmey, C. C., Edgerton, S. M., Yang, X.-H., & Thor, A. D. (2005) · Breast Cancer Research · doi:10.1186/bcr1281 · Cited by 42
Dynamic Analysis of the Epidermal Growth Factor (EGF) Receptor-ErbB2-ErbB3 Protein Network by Luciferase Fragment Complementation Imaging
Macdonald-Obermann, J. L., Adak, S., Landgraf, R., Piwnica-Worms, D. R., & PIKE, L. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.489534 · Cited by 41
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
Swain, S. M., Schneeweiß, A., Gianni, L., Gao, J. J., Stein, A., Waldron-Lynch, M., Heeson, S., Beattie, M. S., Yoo, B., Cortés, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw695 · Cited by 41
The Prognostic Impact of HER2 Genetic and Protein Expression in Pancreatic Carcinoma—HER2 Protein and Gene in Pancreatic Cancer
Han, S., Ryu, K. H., & Kwon, A. (2021) · Diagnostics · doi:10.3390/diagnostics11040653 · Cited by 41
A Conformationally Constrained Peptidomimetic Binds to the Extracellular Region of HER2 Protein
Banappagari, S., Ronald, S., & Satyanarayanajois, D. S. (2010) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2010.10507360 · Cited by 41
EGFR and HER-2 antagonists in breast cancer.
O’Donovan, N., & Crown, J. P. (2007) · PubMed · Cited by 41
Overcoming Treatment Resistance in HER2-Positive Breast Cancer
Puglisi, F., Minisini, A. M., Angelis, C. D., & Arpino, G. (2012) · Drugs · doi:10.2165/11634000-000000000-00000 · Cited by 41
A growing family: Adding mutated Erbb4 as a novel cancer target
Rudloff, U., & Samuels, Y. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11239 · Cited by 40
Dynamic disordering of liposomal cocktails and the spatio-temporal favorable release of cargoes to circumvent drug resistance
Liu, Y., Li, L., Qi, G., Chen, X., & Wang, H. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.089 · Cited by 40
Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options
Jiang, H., & Rugo, H. S. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015599389 · Cited by 40
Changing strategies for target therapy in gastric cancer
Lee, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.1179 · Cited by 40
Targeted Therapy in Uterine Serous Carcinoma: An Aggressive Variant of Endometrial Cancer
Black, J. D., English, D. P.-G., Roque, D. M., & Santin, A. D. (2013) · Women s Health · doi:10.2217/whe.13.72 · Cited by 41
Aspirin inhibits ErbB2 to induce apoptosis in cervical cancer cells
Xiang, S., Sun, Z., He, Q., Yan, F., Wang, Y., & Zhang, J. (2009) · Medical Oncology · doi:10.1007/s12032-009-9221-0 · Cited by 40
Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer
Johnson, B. E., & Janne, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0629 · Cited by 40
Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies
Fu, W., Wang, Y., Zhang, Y., Xiong, L., Takeda, H., Ding, L., Xu, Q., He, L., Tan, W., Bethune, A. N., et al. (2014) · mAbs · doi:10.4161/mabs.28786 · Cited by 39
New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab
Akbari, V., Chou, C.-H. P., & Abedi, D. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188448 · Cited by 39
Receptor-Targeted Cancer Therapy
Richter, M., & Zhang, H. (2005) · DNA and Cell Biology · doi:10.1089/dna.2005.24.271 · Cited by 39
Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies
Asić, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.004 · Cited by 38
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study
Smyth, L. M., Iyengar, N. M., Chen, M. F., Popper, S. M., Patil, S. N., Wasserheit-Lieblich, C., Argolo, D. F. S. D. T. E., Singh, J. C., Chandarlapaty, S., Sugarman, S. M., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3851-7 · Cited by 39
Immunotherapy for breast cancer: past, present, and future
Spellman, A., & Tang, S.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9654-9 · Cited by 39
B-Cell Epitope Peptide Cancer Vaccines: A New Paradigm for Combination Immunotherapies with Novel Checkpoint Peptide Vaccine
Kaumaya, P. T. P. (2020) · Future Oncology · doi:10.2217/fon-2020-0224 · Cited by 38
HER-2-Positive Breast Cancer
Bartsch, R., Wenzel, C., Zielinski, C. C., & Steger, G. G. (2007) · BioDrugs · doi:10.2165/00063030-200721020-00001 · Cited by 38
Design and Applications of Bispecific Heterodimers: Molecular Imaging and beyond
Luo, H., Hong, H., Yang, S. P., & Cai, W. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500115x · Cited by 37
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes
Liu, X., Song, Y., Cheng, P., Liang, B., & Xing, D. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102826 · Cited by 37
Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer
Sachdev, J. C., & Jahanzeb, M. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.07.001 · Cited by 37
Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
Maria, B., Sims, A. H., & Simon, P. L. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0062 · Cited by 37
Biology of the Epidermal Growth Factor Receptor Family
Barnes, C. J., & Kumar, R. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-7847-1_1 · Cited by 37
Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo
Foy, K. C., Miller, M. J., Moldovan, N. I., Carson, W. E., & Kaumaya, P. T. P. (2012) · OncoImmunology · doi:10.4161/onci.20708 · Cited by 36
EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44
Pályi‐Krekk, Z., Barok, M., Kovács, T., Saya, H., Nagano, O., Szöllõsi, J., & Nagy, P. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.01.014 · Cited by 36
Pertuzumab
Keating, G. M. (2012) · Drugs · doi:10.2165/11209000-000000000-00000 · Cited by 36

Authors: Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., Scher, H. I., & Sliwkowski, M. X.
Affiliations: Cedars-Sinai Medical Center (US)
Genentech (US)
Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Sliwkowski, Mark X
ORCID: Agus, David B
Scher, Howard I
Sliwkowski, Mark X
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2002-08
Volume: 2
Issue: 2
Pages: 127-137
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/s1535-6108(02)00097-1
OpenAlex: W2014457594
Cited by: 873
References: 83
Citations by year: 2026: 2 · 2025: 10 · 2024: 21 · 2023: 38 · 2022: 21 · 2021: 21 · 2020: 28 · 2019: 29 · 2018: 27 · 2017: 24 · 2016: 38 · 2015: 48 · 2014: 69 · 2013: 59 · 2012: 51
FWCI: 16.85
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 4003 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: PepsiCo
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: ERBB2, HER2, HER3, neuregulin-1, ErbB receptor family, breast cancer, prostate cancer, tumor growth inhibition, tyrosine kinase inhibitors
MeSH terms: Androgens, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Cell Division, Female, Humans, Ligands, Male, Neoplasm Transplantation, Prostatic Neoplasms, Protein Binding, RNA, Messenger, Time Factors, Transplantation, Heterologous, Tumor Cells, Cultured, Signal Transduction, Gene Expression Regulation, Neoplastic, Erb-b2 Receptor Tyrosine Kinases, Neuregulin-1, Receptor, ErbB-3, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks